Literature DB >> 30443790

Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis.

Wenjia Sun1, Lizhen Tian1,2, Lichun Jiang1,3, Songzhao Zhang4, Meiju Zhou1, Jianing Zhu1, Jing Xue5.   

Abstract

OBJECTIVE: To determine the serum levels of Dickkopf-1 (DKK-1) and sclerostin, as well as their correlations with the structural damage assessed by modified stoke ankylosing spondylitis spine score (mSASSS) and the disease activity evaluated by ankylosing spondylitis disease activity score (ASDAS) in patients with ankylosing spondylitis (AS).
METHODS: Eighty-eight AS patients, 26 rheumatoid arthritis (RA) patients, and 26 age- and gender-matched healthy controls (HC) were collected from rheumatic clinic of the Second Affiliated Hospital of Zhejiang University, School of Medicine, between March 2015 and July 2015. Demographic data, parameters of ASDAS, and image evaluations of spine (i.e., mSASSS) were collected. The serum levels of DKK-1 and sclerostin were measured using commercially available ELISA kits.
RESULTS: Both DKK-1 and sclerostin were significantly higher in the AS patients than in the controls (1855 ± 84.58 vs. 1406 ± 99.76 pg/ml and 106 ± 6.75 vs. 62.78 ± 6.39 pmol/l, respectively, P < 0.05). The correlation analysis suggested a negative correlation between serum sclerostin and mSASSS (P = 0.019, r2 = 0.062). DKK-1 had a trend of positive correlation with mSASSS, but was not statistically significant (P > 0.05). There was no association between the serum levels of DKK-1 or sclerostin and disease activity assessed by ASDAS (P > 0.05). DKK-1 and sclerostin had a negative correlation (P = 0.013, r2 = 0.07).
CONCLUSION: In the present study, the expressions of serum DKK-1 and sclerostin were independent of disease activity. Sclerostin was negatively correlated with the mSASSS, which suggests that sclerostin may be a potential marker indicating the spine ossification process in AS. The specific mechanism remains to be investigated.

Entities:  

Keywords:  AS disease activity score (ASDAS); Ankylosing spondylitis; Dickkopf-1 (DKK-1); Modified stoke ankylosing spondylitis spine score (mSASSS); Sclerostin

Mesh:

Substances:

Year:  2018        PMID: 30443790     DOI: 10.1007/s10067-018-4356-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  6 in total

Review 1.  Biomarkers in axial spondyloarthritis and low back pain: a comprehensive review.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2021-10-21       Impact factor: 2.980

2.  Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis.

Authors:  Yan-Mei Mao; Tao Liao; Qian-Ling Ye; Guo-Cui Wu; Qin Zhang; Sha-Sha Tao; Chan-Na Zhao; Qian Wu; Yi-Lin Dan; Hai-Feng Pan; Dong-Qing Ye
Journal:  Z Rheumatol       Date:  2021-09-20       Impact factor: 1.372

3.  Effect of Warming Yang, Tonifying Kidney, and Removing Arthralgia Therapy on Cold-Dampness Arthralgia Type Ankylosing Spondylitis and Its Influence on the Levels of Humoral Factor in Human Serum.

Authors:  Jing Li
Journal:  Biomed Res Int       Date:  2022-05-09       Impact factor: 3.246

4.  Clinical significance and prognostic value of tumor necrosis factor-α and dickkopf related protein-1 in ankylosing spondylitis.

Authors:  Jun-Hui Xiong; Jian Liu; Jian Chen
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

Review 5.  Bone Involvement in Patients with Spondyloarthropathies.

Authors:  Willem Lems; Corinne Miceli-Richard; Judith Haschka; Andrea Giusti; Gitte Lund Chistensen; Roland Kocijan; Nicolas Rosine; Niklas Rye Jørgensen; Gerolamo Bianchi; Christian Roux
Journal:  Calcif Tissue Int       Date:  2022-01-23       Impact factor: 4.333

6.  The comparison of effects of balneotherapy, water-based and land-based exercises on disease activity, symptoms, sleep quality, quality of life and serum sclerostin level in patients with ankylosing spondylitis: A prospective, randomized study.

Authors:  Ersin Bestaş; Ümit Dündar; Tülay Köken; Buğra Koca; Hilal Yeşil
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.